SOX13 and neoplasm: In another cohort of patients who received cisplatin-based neoadjuvant chemotherapy (n = 52) (Supplementary Table 2)10, high coexpression of SOX13/SCAF1 was positively correlated with poor response to chemotherapy as evidenced by higher tumor regression grades (TRG) (Supplementary Table 6).